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CAsE rEPorT
A 45-year old male patient presented at the Oral and Maxillo-
facial Clinic, Tygerberg, with a pathological fracture of the left 
mandible following an extraction. The medical records of the 
patient revealed a history of multiple myeloma that was treated 
with Aredia (pamidronate disodium, an intravenous form of bi-
sphosphonate), cyclophosphamide (an alkylating agent) and 
dexamethaxone (an anti-inflammatory and immunosuppres-
sant drug). An orthopantomograph revealed osteonecrosis 
and pathological fracture of the left mandible, thought to be 
due to the earlier biphosphonate administration. The patient 
received conservative management for the osteonecrosis 
and was stable at the time of the publication, (19 months after 
the initial presentation with the pathological fracture). 
Clinical assessment during a routine follow-up visit, (31 
months after treatment of multiple myeloma), revealed a flat, 
black pigmented lesion on the posterior part of the hard pal-
ate and involving the soft palate. The lesion had a slightly 
rough surface and measured 25 x 13mm in size (Figure 1). 
The patient had not noticed the lesion before and he had 
experienced neither pain nor discomfort in the area. Apart 
from a small polypoid lesion on the right buccal mucosa, no 
other oral or cutaneous lesions were present. An incisional 
biopsy of the palatal lesion was performed and the buccal 
polypoid lesion was removed at the same time.
Both tissue samples were fixed in 10% buffered formalin and 
submitted to the National Health Laboratory Service (NHLS) 
for histological evaluation. Histopathological assessment of 
the lesion on the buccal mucosa disclosed a squamous 
papilloma whilst the incisional biopsy from the pigmented 
lesion showed a malignant melanoma in situ (Figure 2). The 
patient was subsequently referred for complete removal of 
the palatal lesion.  Histopathological assessment of the ex-
cised specimen showed an invasive malignant melanoma 
with a prominent in situ component (see Figure 3-5). Inva-
sive melanoma involved the anterior margin of the biopsy. 
However, anatomical constraints prevented more extensive 
removal of the melanoma and therefore the patient was 
scheduled for postoperative radiotherapy. Regular follow-up 
assessments of the patient revealed absence of recurrent 
melanoma or metastases 10 months postoperatively.  
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OMM:  Oral mucosal melanoma   
figure 1: A black pigmented lesion involves the posterior part of the hard palate 
and extends onto the soft palate. The ligatures seen on the premolars had been 
used for stabilising the pathological fracture of the left mandible.
figure 2: Histopathological assessment of the palatal lesion at low power mag-
nification shows nests of atypical melanocytes at the epithelial connective tissue 
interface (white arrows). Melanophages are also seen in the superficial connective 
tissue (block arrow). (Haematoxylin and eosin stain)
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introduction 
Melanomas are malignant neoplasms of melanocytes that 
derive from the neuroectoderm.  Although the majority of 
melanomas involve the skin they can occur in any tissue 
containing melanocytes including the mucosa of the oral cavity, 
nasopharynx, eye, genital tract and anorectum. Oral mucosal 
melanoma (OMM) is a rare neoplasm that accounts for less than 
0.5% of all oral malignancies and 0.2- 8% of all melanomas.1-12 
Whilst melanocytes in the skin offer a protective function against 
ultraviolet light, their function in the oral mucosa is unknown 
and in the mucosal tissues they do not produce melanin under 
normal physiological states.1,2,5 Skin melanomas and OMM differ 
significantly in many respects. The mean age of onset of OMM 
is roughly a decade later than its cutaneous counterpart. The 
latter is a multi-factorial disease with evidence of genetic and 
ultraviolet light exposure as predisposing factors. As can be 
expected, mucosal melanomas are not influenced by sunlight 
and they also seem to have a different genetic background. For 
instance, cutaneous melanomas generally show alterations in 
the BRAF oncogene, (a gene that produces a protein that plays 
a role in regulating the signalling pathways for cell division and 
differentiation) whilst most OMM show an over-expression in 
c-KIT, a receptor tyrosine kinase that is a key regulator of growth, 
differentiation, migration and proliferation of melanocytes.7,10,13 In 
addition, patients with OMM more frequently present with a more 
advanced stage of disease than skin lesions, due to the lack 
of early symptoms and relative inaccessibility. OMM therefore 
shows a poorer prognosis and limited 5-year survival rate in 
comparison to cutaneous melanoma. 
In the present case, the OMM occurred some time after the 
patient received treatment for multiple myeloma, raising the 
question: is there any association between multiple myeloma 
and malignant melanoma? A recent report from a health-
based social website states that in a group of 56,677 persons 
with multiple myeloma, 146 (or 0.26%) reported also having 
malignant melanoma.14 This number comprises only 0.63% 
of the 23,123 persons with malignant melanoma reported on 
the same website and is probably not statistically significant. 
Although melanoma may occur more frequently in patients 
with preceding lymphoma, a similar association has not been 
established for myeloma.15 It is theoretically possible that 
treatment with drugs affecting the immune status of a patient 
may stimulate an existing malignancy. However, this is purely 
speculation and will have to await more definitive analysis. 
The association with myeloma, reported in this patient, should 
thus be considered as purely coincidental.
clinical presentation
The most common site for OMM is the hard palate, which 
accounts for 40% of all melanomas of the oral cavity. The 
maxillary gingiva and the alveolar ridge are the second 
most common sites, however, other oral sites can also be 
involved but OMM only rarely involves the mandibular gin-
giva.2,5,11,12 The peak incidence is in the 5th to 7th decades 
of life with a predilection for males (M: F = 2:1).5 The lesion 
is usually asymptomatic and the diagnosis is thus often de-
layed except in patients who seek routine dental treatment or 
present for management of aesthetic problems.11,12  Clinically, 
OMM varies from a macule to a nodule to a large exophytic 
mass with variable pigmentation. The border is usually ir-
regular but is often well demarcated from the surrounding 
mucosa whilst the surface of the lesion may be wrinkled.12 
The clinical differential diagnosis should at least include oral 
melanocytic naevi, melanoacanthoma and Kaposi sarcoma 
in addition to OMM.
The aetiological factors associated with OMMs are unknown 
and as may be expected, there is no association with sun 
exposure.2,4 A history of a previous pigmented lesion, prior 
to the appearance of OMM, has been reported and contra-
dictory reports have been published about the association 
between oral melanosis associated with tobacco usage, and 
oral malignant melanoma.5,6,12 Tobacco and formaldehyde 
exposure have been proposed as possible aetiological fac-
tors for OMM.12 Mucosal malignant melanoma is seen more 
frequently in some population groups from Asia, some parts 
of Africa and Japan.1 
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figure 4: Malignant melanoma in situ extends into the underlying salivary gland 
ducts (arrows) (H&E stain, original magnification x100).
figure 5: Melan A immunohistochemical stain, a marker of melanocytic differen-
tiation, highlights intraepithelial pagetoid spread as well as malignant melanocytes 
at the epithelial-connective tissue interface and in the superficial connective tissue 
(original magnification x100).
figure 3: Malignant melanocytes extend into the epithelial layer in the form of 
nests and single cells, a feature known as intraepithelial pagetoid spread (arrows). 




The histomorphology of mucosal melanoma is variable and 
this is further complicated by non- pigmented and pig-
mented patterns. In malignant melanoma in situ, atypical 
melanocytes are distributed in a nested arrangement at the 
epithelium/connective tissue junction and with intraepithelial 
pagetoid spread, as seen in Figures 1 and 2 in the present 
case. Invasive OMM is characterised by invasion of malig-
nant melanocytes into the underlying connective tissue, re-
ferred to as vertical growth. The malignant cells can vary in 
shape from spindled, epithelioid and plasmacytoid cells to 
small round blue cells. Confirmation of the melanocytic na-
ture of the lesion can be done using immunohistochemical 
markers such as HMB45, Melan A or S100.7,11,12
OMM is a very aggressive disease usually presenting at an 
advanced stage. Usually no radial growth phase is observed 
in these lesions whilst a vertical (or nodular) growth phase 
occurs early thus leading to an advanced stage at presenta-
tion.2,4 Unlike dermal melanomas, oral melanomas are clas-
sified histologically as in situ melanoma, invasive melanoma 
or combined in situ and invasive melanoma. Lesions that 
have uncertain histomorphological features of malignancy 
are termed atypical melanocytic hyperplasia.2 
Molecular features of OMM
The molecular features of OMM are not as well established 
as those of cutaneous malignant melanoma largely due to the 
relative rarity of the former. Recent genetic studies identified 
mutations in DNA repair mechanisms that may be involved in 
the pathogenesis of OMM. These pathways include altera-
tions in cyclin dependant kinase (CDKN2A) and mitogen-ac-
tivated protein kinase (MAPK) pathways.4, 6 The former path-
way is important in cell cycle regulation and the latter in cell 
growth and survival.4 As mentioned earlier, mutations in c-KIT 
(tyrosine receptor kinase) have been observed in 88% of oral 
melanomas, thus suggesting that the use of tyrosine receptor 
kinase inhibitors could be of therapeutic value in the manage-
ment of head and neck mucosal melanomas.7,10,13 
Management and prognosis
The prognosis of OMM is very poor and the 5-year survival 
rate of patients is in the order of 15% but this depends on the 
stage of the disease. Microstaging according to the guide-
lines for cutaneous melanoma, and in particular Clark levels 
and Breslow thickness, does not apply to OMM. The Ameri-
can Joint Committee on Cancer (AJCC) has a staging sys-
tem for OMM which includes features of the primary tumour, 
lymph node status and metastases (TNM).16 Primary OMM 
confined to the mucosal epithelium is normally regarded 
as a T3 lesion to indicate its aggressive clinical course.2,7 
The poor prognosis of OMM, compared with cutaneous 
melanoma, relates to an advanced stage of development 
at the time of the patient’s initial presentation.9 It should be 
stressed, however, that OMM is potentially curable if the tu-
mour is diagnosed at an early stage when the lesion is still in 
its in situ phase and amenable to total surgical removal.12
Several clinical and pathological indicators have been 
shown to be associated with a poor prognosis in cutane-
ous melanomas. These include old age, male gender, spe-
cific sites such as the back, neck and acral skin and lymph 
node involvement. Likewise, the Breslow thickness and the 
presence of surface ulceration are histological indicators of 
poor overall survival and distant metastasis.7 Other histologi-
cal factors of poor prognosis are perineural invasion, lym-
phovascular invasion and increased mitotic activity. On the 
contrary, the presence of tumour-associated lymphocytes is 
linked with a more favourable prognosis.8 Such prognostic 
factors, in cases of OMM and head and neck melanoma, 
are yet to be established and the cutaneous parameters for 
OMMs do not apply, largely due to the anatomic complexity 
of the head and neck region.8
OMM is treated by surgical excision, with clear mucosal 
margins, and the use of additional radiotherapy and chemo-
therapy in specific cases.11 
ConCLUsion
Due to a lack of symptoms in the early stages of OMM, 
patients usually present late and early detection is thus un-
common. The importance of early detection and diagnosis 
cannot be overemphasised as it dramatically improves the 
prognosis. A high index of suspicion is needed when evaluat-
ing pigmented lesions of the oral cavity particularly in high-risk 
areas such as the gingiva and the palate. Oral health care 
practitioners need to approach all oral pigmented lesions with 
circumspection with due regard for the variable morphology 
and asymptomatic nature of OMM, which may prevent early 
detection and diagnosis. Moreover, information on the aetio-
pathogenesis of and the risk factors associated with mucosal 
melanoma is still sketchy and is open for future investigation.
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